French authorities have spent more than three years investigating whether Sanofi downplayed the danger birth defects linked to its valproate-based anti-epilepsy med Depakine. Now, that probe has ...

For years, Sanofi has faced a French probe into birth defects tied to epilepsy medicine Depakine, and now the investigation is moving forward on manslaughter charges. Authorities in France are ...

Paris, France – December 17, 2025. Sanofi announced today that its Q4 2025 Aide memoire is available on the "Investors" page of the company's website: Fourth quarter & full year 2025 results ...

PARIS – June 16, 2020 – Sanofi today detailed plans on how the Company will make significant investments in France to increase its vaccines research and production capacities, and contribute in ...

In key news on French stocks, Sanofi S.A. (FR:SAN) is reportedly planning to revamp its U.S. vaccine operations, including trimming some jobs. As per Endpoint News, the move is part of the pharma ...

Last week, Sanofi SA (NASDAQ:SNY) said it is negotiating with Clayton Dubilier & Rice (CD&R) to potentially sell a 50% controlling stake in Opella, its consumer healthcare business. In October 2023, ...

FILE - In this photo Nov.30, 2020 file photo the logo of French drug maker Sanofi is picture at the company's headquarters, in Paris. French drug maker Sanofi said Wednesday it will help manufacture ...

Sanofi's $2.2 billion commitment to beefing up its messenger RNA work, unveiled in June 2021, has come into clearer view this week with more than a billion dollars of that sum now earmarked toward ...

Sanofi has invested €50 million ($59 million) in French VC firm Jeito Capital. The investment, Sanofi’s first in a private French fund, boosts Rafaèle Tordjman’s efforts to establish Jeito as an ...

PARIS, Sept 6 (Reuters) - A coronavirus vaccine that Sanofi (SASY.PA), opens new tab is developing with Britain's GlaxoSmithKline (GSK.L), opens new tab is likely to be priced at less than 10 euros ...